Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center Abstract #1020

Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).
Aim(s): To assess the efficacy of PRRT in NETs.
Materials and methods: Retrospective analysis was performed using a database in 1000 patients (age 4-85 years) with metastatic and / or progressive NETs, undergoing 1-9 cycles of PRRT at our center, using Lu-177 (n=331), Y-90 (n=170) or both (n=499). Median total administered activity was 17.5 GBq. They were followed up for up to 132 months after the 1st cycle of PRRT. Well-differentiated NETs (G1-2) accounted for 54%. Most patients (95.6%) had undergone at least one previous therapy (surgery 86.8%, medical therapy 55%, ablative therapy 14.2% and radiotherapy 3.4%).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Richard P Baum
Keywords: PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1570 Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years
Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Harshad Kulkarni
Keywords: PRRT, Survival, PET/CT
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#1944 Predictive Value of Baseline Hematology Parameters on Outcome of 177Lu-DOTATOC PRRT
Introduction: In external beam radiotherapy it has been well established that improved tissue O2 increases therapy efficacy, likely mediated by O2 derived free radicals. Additionally, emerging evidence suggests immuno-stimulatory effects of radiotherapy through activation of lymphocytes.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Dr. Cornelis van Echteld
Authors: Kluge A, Baum R, Kulkarni H, Niepsch K, ...
#2845 Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?
Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: PD Dr. Daniel Kaemmerer
#1827 Primary Tumor Resection Results in Superior Overall Survival after Peptide Receptor Radionuclide Therapy in Advanced Neuroendocrine Neoplasms
Introduction: Peptide receptor radionuclide therapy (PRRT) is an highly effective therapeutic option to treat advanced neuroendocrine neoplasms (NEN). However, it is still unclear whether resection of primary tumors improves overall survival (OS) after PRRT.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: PD Dr. Daniel Kaemmerer
Keywords: PRRT, surgery